Procept Biorobotics Corp. ( (PRCT) ) has released its Q2 earnings. Here is a breakdown of the information Procept Biorobotics Corp. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PROCEPT BioRobotics Corporation, a surgical robotics company specializing in urology, is known for its innovative solutions like Aquablation therapy, which aims to improve patient care and outcomes in the treatment of benign prostatic hyperplasia (BPH).
In its latest earnings report for the second quarter of 2025, PROCEPT BioRobotics announced a significant revenue increase of 48% year-over-year, reaching $79.2 million. This growth is attributed to strong demand for its robotic systems and consumables, particularly in the U.S. market. The company also revised its full-year revenue guidance upwards to $325.5 million, reflecting a 45% growth compared to the previous year.
Key financial highlights include a 58% increase in U.S. handpiece and consumables revenue, a 24% rise in U.S. system and rental revenue, and a notable 69% growth in international revenue. The company’s gross margin improved to 65% due to operational efficiencies and higher selling prices. Despite a net loss of $19.6 million, this was an improvement from the previous year’s loss, and the adjusted EBITDA loss also narrowed significantly.
Looking ahead, PROCEPT BioRobotics is optimistic about its growth prospects, driven by its strategic focus on expanding Aquablation therapy usage, increasing market penetration, and advancing international commercial efforts. The appointment of Larry Wood as the new CEO is expected to further strengthen the company’s leadership in the global medical technology industry.